MRKMerck & Co Inc

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced early components of a multi-faceted strategy to provide rapid, broad and sustainable access in low- and middle-income countries (LMICs) to alimatravir (MK-8527), an investigational, novel, once-monthly oral...

GILD's HIV franchise gains momentum with strong Biktarvy and Descovy demand, Yeztugo growth and a promising pipeline targeting long-term expansion.

Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer PR Newswire SOMERVILLE, Mass., July 23, 2026 Veteran pharmaceutical executive to lead Tessera's next phase of growth as the...

GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HIV, RI&I and oncology drugs despite legacy pressures.

Drugmakers have announced 37 biotech acquisitions worth at least $1 billion this year, topping the previous annual record.

ABBV's Q2 oncology revenues may edge lower as Imbruvica weakness outweighs gains from Venclexta and newer cancer therapies.

Keytruda is expected to drive another strong quarter for MRK, with investors watching Q2 sales and management's outlook ahead of the drug's 2028 patent expiry.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the 26th International AIDS Conference (AIDS 2026) taking place in Rio de Janeiro, Brazil, from July 26-31. As a leader in HIV innovation, Gilead will share new scientific data from its HIV research and development...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the detailed outcomes from the Phase 3 ISLEND-1 and ISLEND-2 trials will be presented for the first time at the 26th International AIDS Conference (AIDS 2026). The...